Aerobic exercise for vasomotor menopausal symptoms: A cost-utility analysis based on the Active Women trial

<strong>Objective</strong> To compare the cost-utility of two exercise interventions relative to a control group for vasomotor menopausal symptoms. <strong>Design</strong> Economic evaluation taking a UK National Health Service and Personal Social Services perspective and...

Full description

Bibliographic Details
Main Authors: Goranitis, I, Bellanca, L, Daley, A, Thomas, A, Stokes-Lampard, H, Roalfe, A, Jowett, S
Format: Journal article
Published: Public Library of Science 2017
Description
Summary:<strong>Objective</strong> To compare the cost-utility of two exercise interventions relative to a control group for vasomotor menopausal symptoms. <strong>Design</strong> Economic evaluation taking a UK National Health Service and Personal Social Services perspective and a societal perspective. <strong>Setting</strong> Primary care. <strong>Population</strong> Peri- and postmenopausal women who have not used hormone therapy in the past 3 months and experience ≥ 5 episodes of vasomotor symptoms daily. <strong>Methods</strong> An individual and a social support-based exercise intervention were evaluated. The former (Exercise-DVD), aimed to prompt exercise with purpose-designed DVD and written materials, whereas the latter (Exercise-Social support) with community exercise social support groups. Costs and outcomes associated with these interventions were compared to those of a control group, who could only have an exercise consultation. An incremental cost-utility analysis was undertaken using bootstrapping to account for the uncertainty around cost-effectiveness point-estimates. <strong>Main outcome measure</strong> Cost per quality-adjusted life-year (QALY). <strong>Results</strong> Data for 261 women were available for analysis. Exercise-DVD was the most expensive and least effective intervention. Exercise-Social support was £52 (CIs: £18 to £86) and £18 (CIs: -£68 to £105) more expensive per woman than the control group at 6 and 12 months post-randomisation and led to 0.006 (CIs: -0.002 to 0.014) and 0.013 (CIs: -0.01 to 0.036) more QALYs, resulting in an incremental cost-effectiveness ratio of £8,940 and £1,413 per QALY gained respectively. Exercise-Social support had 80%-90% probability of being cost-effective in the UK context. A societal perspective of analysis and a complete-case analysis led to similar findings. <strong>Conclusions</strong> Exercise-Social support resulted in a small gain in health-related quality of life at a marginal additional cost in a context where broader wellbeing and long-term gains associated with exercise and social participation were not captured. Community exercise social support groups are very likely to be cost-effective in the management of vasomotor menopausal symptoms.